Donovan Quill 0 Podcast February 19, 2021 Announcing Rare Voices Season Two: Onward Rare Voices · Announcing Rare Voices Season Two: Onward We started this show a few…Read More
Donovan Quill 0 Podcast February 12, 2021 Rare Voices S1E7: Donovan Quill and Michelle Hefley, cofounders of Optime Care Rare Voices · S1E7: Donovan Quill and Michelle Hefley, cofounders of Optime Care For…Read More
Donovan Quill 0 Articles December 8, 2020 The Proven Model for Improving Clinical Trial Results During the Pandemic The pharmaceutical industry has not escaped the impact of the COVID-19 crisis. Every phase of…Read More
Michelle Hefley 0 Articles November 23, 2020 How to Build an Integrated Service Model for Rare and Orphan Drugs Six Questions You Should Ask a Consultant Many drug manufacturers and healthcare consultants attempt to…Read More
Donovan Quill 0 Podcast November 20, 2020 Rare Voices S1E6: Monica Weldon, Bridge the Gap: SYNGAP Education and Research Foundation Rare Voices · S1E6: Monica Weldon, Founder of Bridge the Gap: SYNGAP Education and Research…Read More
Donovan Quill 0 Podcast November 2, 2020 Rare Voices S1E5: Dave Penake, Saol Therapeutics Rare Voices · S1E5: David Penake, Saol Therapeutics Anyone who has invested their time in…Read More
Donovan Quill 0 Articles October 16, 2020 9 Steps to Improving Patient Access to Rare and Orphan Drugs A conversation on eHealth Radio Recently, I had the privilege of a thought-provoking conversation on…Read More
Donovan Quill 0 Podcast September 24, 2020 Rare Voices S1E4: Bill Jollie, Global Pharmaceutical https://soundcloud.com/rare-voices/s1e4-bill-jollie-global-pharmaceutical In healthcare, it is easy to become cynical. We are surrounded by the shortcomings…Read More
Donovan Quill 0 Articles September 22, 2020 How to Stay Focused on Rare and Orphan Disorders in the Time of COVID 4 Critical Success Factors for Manufacturers Before I became president and CEO of Optime Care,…Read More
Donovan Quill 0 Articles August 20, 2020 Product First Means Patients Left Behind A tale of too many patients. My family has a long history of alpha-1 antitrypsin…Read More